AMENDMENT NO. 1 TO CONSULTING SERVICES AGREEMENT
Exhibit 10.1
AMENDMENT NO. 1
TO
This Amendment No. 1 (this “Amendment”), is made and entered into as of March 23, 2023, by and between Aclaris Therapeutics, Inc., a Delaware corporation (the “Company”) and Xxxxx Xxxxx (“Consultant”).
WHEREAS, the Company and Consultant entered into that certain Consulting Services Agreement, dated as of January 1, 2023 (the “Agreement”), and desire to extend the term of the Agreement and modify Consultant’s compensation.
NOW THEREFORE, in consideration of the mutual promises set forth herein, and intending to be legally bound hereby, the parties hereby agree as follows:
“1.2.1. In consideration of Consultant’s performance of the Services, the Company shall pay Consultant $12,500 per month (“Consulting Fee”) during the term of this Agreement.”
“1.2.2. Consultant agrees that his last day of Continuous Service (as defined in the Company’s 2015 Equity Incentive Plan) was March 2, 2023, and no outstanding equity awards will vest thereafter.”
“Term. Unless terminated earlier pursuant to Section 5.2 or 5.3, the term of this Agreement shall be from March 3, 2023 through June 30, 2023.”
[Remainder of page intentionally left blank]
IN WITNESS WHEREOF, the parties have caused this Amendment No. 1 to be duly executed as of the date first above written.
CONSULTANT | |||
| | | |
| | | |
By: | /s/ Xxxxxxx Xxxxxx | By: | /s/ Xxxxx Xxxxx |
Name: | Xxxx Xxxxxx | Name: | Xxxxx Xxxxx |
Title: | President & CEO | | |